Financial News
Latest News about MRK
Recent news which mentions MRK
Evercore ISI Group Boosts PT On This Stock By Around 400%, Plus This Analyst Predicts $100 For Merck
September 14, 2022
From Benzinga
AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say
September 14, 2022
From MarketWatch
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
September 13, 2022
From Benzinga
Merck Secures Canadian Regulatory Nod For KEYTRUDA In Skin Cancer After Resection
September 13, 2022
Tickers
MRK
From Benzinga
After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff
September 13, 2022
From Benzinga
Got $1,000? 3 Stocks to Buy and Hold Until Retirement
September 13, 2022
From Motley Fool
BP To $47? Plus UBS Sees $2,260 For This Stock
September 12, 2022
From Benzinga
Five-Year Data For Merck's Keytruda Plus Chemo Shows Sustained Survival Benefit In Lung Cancer Patients
September 12, 2022
Tickers
MRK
From Benzinga
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
September 12, 2022
From Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
September 09, 2022
From Benzinga
Why Shares of Shuttle Pharmaceuticals Jumped 160.4% This Week
September 09, 2022
From Motley Fool
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
September 09, 2022
From Benzinga
Merck's Deal With Seagen May Have Fallen Through. Now What?
September 07, 2022
From Motley Fool
Why Ocugen Stock Topped the Market Today
September 01, 2022
From Motley Fool
From Benzinga
Novartis Appoints Merck Executive As Research Head
September 01, 2022
From Benzinga
Why Guardant Health Crushed the Market Today
August 31, 2022
From Motley Fool
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
August 30, 2022
From Benzinga
Bristol Myers-JNJ Partnered Secondary Stroke Drug Misses Endpoint, But Companies See Enough Potential For Phase 3 Trials
August 29, 2022
From Benzinga
From Benzinga
From InvestorPlace
From Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 25, 2022
From Benzinga
1 Bear Market Blunder Investors Are Still Making
August 25, 2022
From Motley Fool
From Benzinga
From Motley Fool
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 23, 2022
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.